There are 2 sections in this post:
Randomized placebo studies
Other mortality studies
Randomized placebo studies
There are several major difficulties with finding randomized mortality studies for antipsychotics. The first being that the "placebo" group is in fact an abrupt withdrawal group(1). The second being that the studies are usually of young people and for such a short time that not enough deaths occur to have significant data.
However, the drug corporations did do randomized placebo clinical trials on old people with dementia which avoids both those issues.
Before going into those studies it is important to remember that corporate clinical trials hide negative effects including deaths. Previous corporate psych drug clinical trials reported only 38% of deaths(2).
A meta-analysis of corporate 10 week long clinical trials of newer "antipsychotic" drugs and mortality in dementia patients was done and found(3):
Death occurred more often among patients randomized to drugs (118 [3.5%] vs 40 [2.3%].
In the FDA report we find that that death data was underreported. As reported in the beginning of page 4:
Over the course of a typical 10-week controlled trial, the rate of death in drug treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.
10 weeks of use kill 2% of the dementia patients taking these drugs. This is according to studies done by the corporations selling these drugs.
2. Other mortality studies
A 17 year study done in Finland by a psychiatry professor found that "antipsychotics" increased the chance of dying by 2.5 times. Partipcants physical health, mental health, recreational drug use, physical activity, education, and other factors were recorded at baseline(5).
During a 17-year follow-up, 39 of the 99 people with schizophrenia died (40%)
Adjusted for age, gender, somatic diseases and other potential risk factors for premature death, the relative risk was 2.50 per increment of one neuroleptic.
The next study is a 10 year prospective study done in Ireland by the Department of Clinical pharmacology(6). Prospective studies are one of the highest quality type of studies there are. The increased risk of death was 2.46 for antipsychotic use.
Over the decade, 39 of the 88 patients (44%) died,
A third non-randomized study (7) is a very large study done in the UK. There were around 180,000 people in the study that used "antipsychotics"(chart on page 3). This study was funded by the drug corporation Eli Lilly (Disclosure section). While 4 out of 7 of the study authors worked for Eli Lilly.
The study adjusted the mortality data for wide range of variables: (page 5 statistical analyses)
age, sex, socioeconomic status, smoking history, alcohol use, and body mass index. Age, sex, BMI, duration of psychiatric disease, history of cardiovascular disease, alcohol or drug abuse, diabetes mellitus, history of suicide attempt, prior hospital admission for psychiatric disease and prescribing in the 3 months before of statins or fibrates, antihypertensive drugs, warfarin, antiplatelets, nitrates, lithium, antiepileptics, antidepressants, and anxiolytics
Tables 4-5 reports physical mortality rates for various groups.
The drugs increased the rate of dying by 2.72. This study found that people without a psych label who took the drugs had higher mortality rates compared to people with schizophrenia who were not long term users of the drugs.
Table 8 shows a dose dependent relationship, with higher dosages increasing mortality by more then lower doses.
(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971828/
(2) https://bmjopen.bmj.com/content/4/7/e005535.long
(3) https://pubmed.ncbi.nlm.nih.gov/16234500/
(4) https://www.accessdata.fda.gov/drugsatf ... s03lbl.pdf
(5) https://pubmed.ncbi.nlm.nih.gov/16449697/
(6) https://pubmed.ncbi.nlm.nih.gov/9926037/
(7) https://www.ncbi.nlm.nih.gov/pmc/articl ... 247486.pdf
News
Site map
SitemapIndex
RSS Feed